Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and/or Invasive Candidiasis at ECCMID 2022
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cidara Therapeutics (NASDAQ: CDTX) and Mundipharma are set to present new clinical data on rezafungin, a novel echinocandin for treating candidemia and invasive candidiasis, at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from April 23-26, 2022. The data includes results from the global Phase 3 ReSTORE trial and analyses from STRIVE Phase 2 trials. Notably, there will be two late-breaking presentations, highlighting the significant advancements in this promising treatment.
Positive
- Presentation of new clinical data on rezafungin at ECCMID, potentially boosting investor confidence.
- Key results from the Phase 3 ReSTORE trial could indicate strong efficacy and safety for rezafungin, enhancing its market position.
Negative
- None.
Details
News Market Reaction – CDTX
The recorded move for CDTX in the trading session of this news was +2.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO and CAMBRIDGE, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced that the companies will present new clinical data and analyses of rezafungin, a novel, once-weekly echinocandin in development for the treatment of candidemia and invasive candidiasis and prevention of invasive fungal infections, at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), being held virtually and in Lisbon, Portugal, from April 23-26, 2022. The new data will be presented in three presentations, including two late-breaking presentations highlighting full results from the global Phase 3 ReSTORE trial and the integrated analyses from the ReSTORE Phase 3 and STRIVE Phase 2 trials.
Presentation details are as follows:
Oral Presentations:
Title: Venetoclax and Ibrutinib Pharmacokinetics Unaltered when Coadministered with Rezafungin
Presenter: Taylor Sandison, Chief Medical Officer of Cidara Therapeutics
Session: New Insights about PK/PD of antifungal agents, 1-Hour Oral Session (Regular)
Session Date/Time: April 23, 2022, at 12:00 p.m. CEST
Title: Patient-level Meta-Analysis of Efficacy and Safety from STRIVE and ReSTORE: Randomized, Double-blinded, Multicenter Phase 2 and Phase 3 Trials of Rezafungin in the Treatment of Candidemia and/or Invasive Candidiasis
Presenter: Alex Soriano, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Spain
Session: Emerging clinical data and interventional studies, 2-Hour Oral Session (Late-breaker)
Session Date/Time: April 25, 2022, at 9:30 a.m. CEST
Poster Presentation:
Title: ReSTORE: Efficacy and Safety Results of the Phase 3, Noninferiority Trial of Rezafungin in the Treatment of Candidemia and/or Invasive Candidiasis
Presenter: Oliver Cornely, CECAD Institute of the University of Cologne, Germany
Session: 6. Fungal infection & disease, L0244 Poster (Late-breaker)
Session Date/Time: April 25, 2022, at 1:00 p.m. CEST
To register and view the full schedule, visit ECCMID 2022 Conference’s website here. A copy of the presentations can be accessed on the publications section of Cidara’s website once the meeting concludes.
About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to DFCs targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
About Mundipharma
Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East.
Mundipharma is dedicated to bringing innovative treatments to patients in the areas of Pain Management, Infectious Disease and Consumer Healthcare as well as other severe and debilitating disease areas. Our guiding principles, centered around Integrity and Patient-Centricity, are at the heart of everything we do. For more information visit www.mundipharma.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Patrick Bursey
LifeSci Communications
(203) 430-9545
pbursey@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.